CSF3R and chronic neutrophilic leukemia: Similarly, it was found that harboring compound CSF3R mutations, as opposed to isolated proximal or truncation mutations, conferred resistance to Ruxolitinib in a murine model of CNL, suggesting that JAK inhibitors may be of minimal benefit to the ~1/3 of CNL patients exhibiting such compound CSF3R mutations123.